-
Biogen's Parkinson's Antibody Could Boost Prothena, RBC Says
Monday, July 20, 2015 - 10:54am | 330Read More...In a report published Sunday, RBC Capital Markets analyst Michael Yee discussed why it is an "incremental positive" that Biogen Inc (NASDAQ: BIIB)'s new Parkinson's antibody supports his positive thesis on Prothena Corporation PLC. Biogen began a Phase 1 study of its BIIB-054...
-
Large-Cap Biotechs Poised For Second-Half Rally, RBC Says
Thursday, July 9, 2015 - 9:21am | 318Read More...RBC Capital Markets Analyst Michael Yee said in a new research note that the recent 5 to 6 percent pullback in large-cap biotech will provide a good opportunity heading into what they expect will be "mostly in-line to better" earnings. On a macro basis, Yee reiterated the firm's...
-
Top Street Analysts Like Gilead Sciences
Monday, May 18, 2015 - 12:23pm | 454Read More...Gilead Sciences, Inc. (NASDAQ: GILD) has been a favorite among biotech investors due to its successful hepatitis C therapies; Harvoni and Sovaldi. However, the biopharmaceutical company is making headlines again with a new drug for gastric cancer; GS-5745. GS-5745 is advancing into Phase III...
-
Can Gilead Really Post EPS Growth Above 50%?
Wednesday, April 29, 2015 - 4:52pm | 408Read More...Shares of Gilead Sciences, Inc. (NASDAQ: GILD) are down about 1.7 percent on Wednesday afternoon. The company will announce its first quarter financial results on Thursday afternoon, after the market closes. According to Estimize, both the crowd and experts expect to see more than 50 percent...
-
What's Wall Street Been Saying About Gilead Lately?
Wednesday, April 29, 2015 - 12:34pm | 588Read More...Gilead Sciences, Inc. (NASDAQ: GILD) is scheduled to release its first quarter results on Thursday after market close. The Estimize consensus earnings per share estimate (based on 137 estimates) is $2.48 on revenue of $7.049 billion. This compares to the Wall Street Consensus earnings per...
-
Gilead-Vertex Deal Has 'Low Probability' Of Happening, RBC Capital Says
Tuesday, April 21, 2015 - 12:57pm | 346Read More...In a report published Tuesday, RBC Capital Markets analyst Michael Yee commented on the increasing Street "appreciation" over the idea that Gilead Sciences, Inc. (NASDAQ: GILD) should acquire Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX). Yee noted that many investors are working...
-
Will Intercept Pharma Outperform? These Analysts Think So
Friday, March 6, 2015 - 12:40am | 425Read More...Intercept Pharmaceuticals Inc (NASDAQ: ICPT) released its fourth quarter and full year 2014 financial results on March 2. The biopharmaceutical company focuses on chronic liver diseases, although it does not yet produce any drugs of its own. Intercept is in the process of gaining approval for...
-
XenoPort Soars 9% Following Comments From RBC's Michael Yee
Tuesday, December 30, 2014 - 12:38pm | 107Read More...XenoPort, Inc. (NASDAQ: XNPT) soared following comments from RBC’s Michael Yee who called it his “under the radar play” on CNBC. RBC's Michael Yee says Xenoport is his under the radar play for 2015 $XNPT — CNBC's Fast Money (@CNBCFastMoney) December 29, 2014 The...
-
Tuesday's #PreMarket Movers: Neuroderm, Microsoft, Medbox, Civeo And More
Tuesday, December 30, 2014 - 10:17am | 347Read More...Neuroderm Ltd (NASDAQ: NDRM) +30% - The company announced favorable Phase IIa Parkinson’s treatment study results. China Jo-Jo Drugstores Inc (NASDAQ: CJJD) +9% - Shares are higher following a report of potential legalization of online prescription drugs sales in China. XenoPort,...
-
RBC Sees Weak Merck Data As Positive For Gilead
Monday, November 10, 2014 - 10:29am | 181Read More...In a note from RBC Capital analyst Michael Yee, Merck & Co., Inc.'s (NYSE: MRK) weaker-than-expected data for hepatitis C is a net positive for Gilead Sciences, Inc. (NASDAQ: GILD). Merck had looked to shorten hepatitis C treatment by adding Gilead's Sovaldi to its own oral two-drug...
-
Why Investors Should Closely Watch Celgene
Wednesday, August 6, 2014 - 4:53pm | 673Read More...We’re waist-deep into the earnings season, and many companies have already filed. The U.S. biotech firm Celgene Corp (NASDAQ: CELG) has filed as well, and its reported earnings beat Wall Street’s expectations. Here are some takeaways from the report. Earnings Overview Revenues...
-
Tekmira Sinks 15%; Anti-Ebola Drug Trial Halted For Safety Concerns
Thursday, July 3, 2014 - 1:26pm | 218Read More...Tekmira Pharmaceuticals (NASDAQ: TKMR) shares sank 15 percent after the company revealed the Phase I trial of one of its lead drug candidates was put on hold by the Food and Drug Administration for safety concerns. The anti-Ebola virus RNAi drug is being developed under a $140 million contract...
